NO992197L - FremgangsmÕte for behandling av bronkitt med uridintrifosfater og relaterte forbindelser - Google Patents

FremgangsmÕte for behandling av bronkitt med uridintrifosfater og relaterte forbindelser

Info

Publication number
NO992197L
NO992197L NO992197A NO992197A NO992197L NO 992197 L NO992197 L NO 992197L NO 992197 A NO992197 A NO 992197A NO 992197 A NO992197 A NO 992197A NO 992197 L NO992197 L NO 992197L
Authority
NO
Norway
Prior art keywords
uridine
bronchi
clearance
bronchioles
utp
Prior art date
Application number
NO992197A
Other languages
English (en)
Other versions
NO992197D0 (no
Inventor
Christy L Shaffer
Jr Richard C Boucher
Janet L Rideout
Karla M Jacobus
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of NO992197D0 publication Critical patent/NO992197D0/no
Publication of NO992197L publication Critical patent/NO992197L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Fremgangsmåte for å fremme renselse av bibeholdte mukøse sekresjoner i bronkiene, bronkiolene og de små terminals luftveier hos et individ med behov for en slik behandling. Fremgangsmåten omfatter administrering til bronkiene til individet av et uridintrifosfat slik som uridin 5'Jtrifosfat (UTP) eller PI(P4-di(uridin-5I) tetrafosfat (U2P4) , en analog av UTP, eller en hvilken som helst annen analog, i en mengde som er effektiv til å fremme mukociliær renselse og/eller renselse ved hosting av bibeholdt fluid i bronkiene, bronkiolene og de små terminale luftveier. Metoder for administrering av disse vil inkludere aerosolinhalasjon, enhver flytende suspensjon (inkluderende nesedråper eller nesespray), oral form (væske eller piller), injisert intra- operativ inndrypping eller stikkpilleform.
NO992197A 1996-11-07 1999-05-05 FremgangsmÕte for behandling av bronkitt med uridintrifosfater og relaterte forbindelser NO992197L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/744,367 US6159952A (en) 1996-11-07 1996-11-07 Method of treating bronchitis with uridine triphosphate and related compounds
PCT/US1997/018766 WO1998019685A1 (en) 1996-11-07 1997-10-21 Method of treating bronchitis with uridine triphosphates and related compounds

Publications (2)

Publication Number Publication Date
NO992197D0 NO992197D0 (no) 1999-05-05
NO992197L true NO992197L (no) 1999-07-05

Family

ID=24992452

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992197A NO992197L (no) 1996-11-07 1999-05-05 FremgangsmÕte for behandling av bronkitt med uridintrifosfater og relaterte forbindelser

Country Status (14)

Country Link
US (1) US6159952A (no)
EP (1) EP0941099B1 (no)
JP (1) JP2001505553A (no)
KR (1) KR100518066B1 (no)
CN (1) CN1115152C (no)
AT (1) ATE249833T1 (no)
AU (1) AU744981B2 (no)
BR (1) BR9714312A (no)
CA (1) CA2271126C (no)
DE (1) DE69724991T2 (no)
ES (1) ES2207723T3 (no)
NO (1) NO992197L (no)
NZ (1) NZ335540A (no)
WO (1) WO1998019685A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
BRPI9810436B1 (pt) 1997-07-25 2015-12-29 Inspire Pharmaceuticals Inc processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6251693B1 (en) 1998-07-30 2001-06-26 Micron Technology, Inc. Semiconductor processing methods and semiconductor defect detection methods
MXPA01008547A (es) * 1999-02-26 2003-06-06 Inspire Pharmaceuticals Inc Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7109181B2 (en) 2001-06-25 2006-09-19 Inspire Pharmaceuticals, Inc. Joint lubrication with P2Y purinergic receptor agonists
TW200300692A (en) * 2001-11-06 2003-06-16 Inspire Pharmaceuticals Inc Method for treating or preventing inflammatory diseases
EP1560540A4 (en) * 2002-10-18 2008-03-19 Molichem Medicines Inc METHOD FOR TREATING DRY EYES WITH LANTIBIOTICS
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US7479481B2 (en) * 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070249556A1 (en) * 2006-04-21 2007-10-25 Brubaker Kurt E Method of treating inflammation
JP2011026204A (ja) * 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
WO2019112383A1 (ko) * 2017-12-08 2019-06-13 윤주석 금속 미네랄 디아미네이트 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2122529A1 (de) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
US3960840A (en) * 1972-12-29 1976-06-01 University Of Illinois Foundaton Fluorescent derivatives of adenine-containing compounds
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
PL297372A1 (en) * 1991-04-06 1993-09-06 Fisons Plc Atp analogs
FR2684299B1 (fr) * 1991-12-02 1995-03-24 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
FR2677250B1 (fr) * 1991-06-05 1995-01-20 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
KR20000053094A (ko) 2000-08-25
CN1115152C (zh) 2003-07-23
EP0941099B1 (en) 2003-09-17
AU744981B2 (en) 2002-03-07
DE69724991D1 (de) 2003-10-23
BR9714312A (pt) 2000-05-02
DE69724991T2 (de) 2004-11-11
ATE249833T1 (de) 2003-10-15
AU4986697A (en) 1998-05-29
NZ335540A (en) 2001-05-25
CA2271126A1 (en) 1998-05-14
CN1236318A (zh) 1999-11-24
CA2271126C (en) 2008-04-08
EP0941099A1 (en) 1999-09-15
US6159952A (en) 2000-12-12
JP2001505553A (ja) 2001-04-24
ES2207723T3 (es) 2004-06-01
WO1998019685A1 (en) 1998-05-14
KR100518066B1 (ko) 2005-09-28
NO992197D0 (no) 1999-05-05

Similar Documents

Publication Publication Date Title
NO992197L (no) FremgangsmÕte for behandling av bronkitt med uridintrifosfater og relaterte forbindelser
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1997035591B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
DE69716255D1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
NO980279L (no) Fremgangsmåte til detektering av lungesykdom
DE69625906D1 (de) Dinukleotide zur verwendung in der behandlung von lungenkrankheiten
DK0734249T3 (da) Hidtil ukendt og forbedret aminoglycosidformulering til aerosolisering
DE69431290D1 (de) PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1
ES2137371T3 (es) Nuevos compuestos quimicos que tienen actividad de inhibicion de la pde-iv.
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
MD1838G2 (ro) Derivaţi de 5,6-diclorbenzimidazol, procedeu de obţinere a lor, compoziţie farmaceutică şi metodă de tratament sau de prevenire a infecţiei virotice herpetice
SE9502474D0 (sv) Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa
IL142983A0 (en) Nucleosides with anti-hepatisis b virus activity
IL118180A (en) Pharmaceutical compositions comprising a phosphatidic acid (PA) enriched natural phospholipid preparation and the production of such preparation
NZ287291A (en) Tri-aryl-substituted alanineamide derivatives, analogues and medicaments
HUP9802142A2 (hu) Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására
UA30393A (uk) Спосіб лікування коронарного атеросклерозу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application